An adverse effect of amiodaron on the skin


Cite item

Full Text

About the authors

D I Reingardene

References

  1. Jafari-Fesharaki M., Scheinman M. M. Adverse effects of amiodarone. Pacing Clin. Electrophysiol. 1998; 21 (1): 108-120.
  2. Ceremuzynski L., Kleczar E., Kneminska-Pakula M. et al. Effect of amiodarone on mortality after myocardial infarction: a double - blind, placebo - controlled, pilot study. J. Am. Coll. Cardiol. 1992; 20: 1056-1062.
  3. Lee K. L., Tai Y. T. Long - term low - dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmia: efficacy and safety. Clin. Cardiol. 1997; 20 (4): 372-377.
  4. Yazigi A., Rahbani P., Zeid H. A. et al. Postoperative oral amiodarone as prophylaxis against atrial fibrillation after coronary artery surgery. J. Cardiothorac. Vase. Anesth. 2002; 16 (5): 603-606.
  5. Nicklas J. M., McKenna W. J., Stewart R. A. Prospective, double - blind, placebo - controlled trial of low- dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am. Heart J. 1991; 122: 1016-1021.
  6. Naccarelli G. V., Wolbrette D. L., Patel H. M., Luck J. С. Amiodarone: clinical trials. Curr. Opin. Cardiol. 2000; 15 (1): 64- 72.
  7. Kerin N. Z., Faitel K., Kerin I. A. et al. Efficacy of low - dose amiodarone in the prevention of paroxysmal atrial fibrillation resistant to type IA antiarrhythmic drugs. Am. J. Ther. 2000; 7 (4): 245-250.
  8. Kowey P. R., Frichling T. D., Marinchak R. A. et al. Safety and efficacy of amiodarone. The low - dose perspective. Chest 1988; 93: 54-59.
  9. Rappersberger K., Honigsmann H., Ortel B. et al. Photosensitivity and hyperpigmentation in amiodarone - treated patients: incidence, time course, and recovery. J. Invest. Dermatol. 1989; 93: 201-209.
  10. Vorperian V. R., Havighurst T. C., Miller S., January С. Т. Adverse effects of low dose amiodarone: a meta - analysis. J.Am. Coll. Cardiol. 1997; 30 (3): 791-798.
  11. Cairns J. A., Connolly S. J., Gent M., Roberts R. Post - myocardial infarction mortality in patients with ventricular premature depolarization: Canadian myocardial infarction amiodarone trial pilot study. Circulation 1991; 84: 550-557.
  12. Drug - induced cutaneous photosensitivity: some drugs warrant routine precautions. Prescrire Int. 2000; 9 (48): 117-122.
  13. Bosca F., Miranda M. A. Photosensitizing drugs containing the benzophenone chromophore. J. Photochem. Photobiol. В 1998; 43: 1-26.
  14. Auer J., Berent R., Eber B. Amiodarone in the prevention and treatment of arrhythmia. Curr. Opin. Invest. Drugs 2002; 3 (7): 1037-1044.
  15. White C. M., Giri S., Tsikouris J. P. et al. A comparison of two individual amiodarone regimens to placebo in open heart surgery patients. Ann. Thorac. Surg. 2002; 74 (1): 69-74.
  16. Hein L. Amiodarone. Dtsch. Med. Wschr. 2001; 126 (21): 625-626.
  17. Goldschlager N., Epstein A. E., Naccarelli G. et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American Society of pacing and electrophysiology. Arch. Intern. Med. 2000; 160 (12): 1741-1748.
  18. Murphy M. Т., Wilkoff B. L. What internists should know about amiodarone. Cleveland Clin. J. Med. 1998; 65 (3): 159- 166
  19. Rokicki W., Durmala J., Nowakowska E. Amiodarone for long term treatment of arrhythmia in children. Wiad. Lek. 2001; 54 (1-2): 45-50.
  20. Crystal E., Kahn S., Roberts R. et al. Long - term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). J. Thorac. Cardiovasc. Surg. 2003; 125 (3): 633-637.
  21. Brendorp В., Pedersen O., Torp-Pedersen C. et al. A benefitrisk assessment of class III antiarrhythmic agents. Drug Saf. 2002; 25 (12): 847-865.
  22. Lowe N. J. Photosensitivity. Medicine 1988; 49: 2022-2024.
  23. Singh B. N. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin. Cardiol. 1997; 20 (7): 608-618.
  24. Singh S. N., Fletcher R. D., Fisher S. G. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 1995; 333: 77-82.
  25. Zachary С. В., Slater D. N., Holt D. W. et al. The pathogenesis of amiodarone - induced pigmentation and photosensitivity.Br. J. Dermatol. 1984; 110: 451-456.
  26. Sirajudeen K. N., Gurumoorthy P., Devaraj H., Devaraj S. N. Amiodarone - induced phospholipidosis: an in vivo (14C) - acetate uptake study in rat. Drag Chem. Toxicol. 2002; 25 (3): 247-254.
  27. Bianco A. C., Salvatore D., Bereben B. et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 2002; 23 (1): 38-89.
  28. Sivaram С. A., Beckman K. J. Images in clinical medicine. Amiodarone - induced skin discoloration. N. Engl. J. Med. 1997; 337 (25): 1813.
  29. Miller R. A. W., McDonal A. T. Dermal lipofuscinosis associated with amiodarone therapy. Arch. Dermatol. 1984; 120: 646-649.
  30. Wohlrab J., Fischer M., Stoldt G., Marsch W. С 52-year old patient with skin discoloration. Internist (Berl.) 2001; 49 (9): 1256-1260.
  31. Haas N., Schadendorf D., Hermes В., Henz В. М. Hypomelanosis due to block of melanosomal maturation in amiodaroneinduced hyperpigmentation. Arch. Dermatol. 2001; 137 (4): 513-514.
  32. Dereure O. Drug - induced skin pigmentation. Epidemiology, diagnosis and treatment. Am. J. Clin. Dermatol. 2001; 2 (4): 253-262.
  33. Klein A. D., Pardo R. J., Gould E., Kerdel F. Blue - grey discoloration of the face. Amiodarone - induced cutaneous hyperpigmentation. Arch. Dermatol. 1989; 125: 417, 420-421.
  34. Bahadir S., Apaydin R., Cobanoilu U. et al. Amiodarone pigmentation, eye and thyroid alterations. J. Eur. Acad. Dermatol. Venereol. 2000; 14 (3): 194-195.
  35. Kundu A. K. Amiodarone - induced systemic lupus erythematosus. J. Assoc. Physicians India 2003; 51: 216-217.
  36. Yung A., Agnew K., Snow J., Oliver F. Two unusual cases of toxic epidermal necrolysis. Austral. J. Dermatol. 2002; 43: 35- 38.
  37. Mendez M., Parere V., Salamanca R. E., Batlle A. Amiodarone is a pharmacologically safe drug for porphyrias. Gen. Pharmacol. 1999; 32: 259-263.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies